Jianhua Yu

23.4k total citations · 8 hit papers
308 papers, 16.5k citations indexed

About

Jianhua Yu is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Jianhua Yu has authored 308 papers receiving a total of 16.5k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Immunology, 105 papers in Molecular Biology and 86 papers in Oncology. Recurrent topics in Jianhua Yu's work include Immune Cell Function and Interaction (117 papers), CAR-T cell therapy research (49 papers) and T-cell and B-cell Immunology (35 papers). Jianhua Yu is often cited by papers focused on Immune Cell Function and Interaction (117 papers), CAR-T cell therapy research (49 papers) and T-cell and B-cell Immunology (35 papers). Jianhua Yu collaborates with scholars based in United States, China and Macao. Jianhua Yu's co-authors include Michael A. Caligiuri, Aharon G. Freud, Jianying Zhang, Xiaoming He, Tiffany Hughes, Shuting Zhao, Bethany L. Mundy-Bosse, Hsiaoyin Mao, Balveen Kaur and Xiongbin Lu and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Jianhua Yu

301 papers receiving 16.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

2010 660 citations Don M. Benson, Courtney E. Bakan et al. Blood profile →
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver

2012 623 citations Shu‐Hao Hsu, Jianhua Yu et al. profile →
The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation

2020 530 citations Qinglv Wei, Qingya Luo et al. profile →
The Broad Spectrum of Human Natural Killer Cell Diversity

2017 482 citations Aharon G. Freud, Bethany L. Mundy-Bosse et al. profile →
Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

2018 356 citations Ansel P. Nalin, Jianhua Yu et al. profile →
The emerging field of oncolytic virus-based cancer immunotherapy

2022 182 citations Zhenlong Li, Michael A. Caligiuri et al. profile →
Targeting the RNA m6A modification for cancer immunotherapy

2022 159 citations Xinxin Li, Shoubao Ma et al. profile →
YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells

2023 143 citations Shoubao Ma, Tasha Barr et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jianhua Yu United States	71	6.9k	6.3k	5.5k	2.3k	1.8k	308	16.5k
Pan Zheng United States	63	6.0k 0.9×	6.8k 1.1×	3.4k 0.6×	1.8k 0.8×	708 0.4×	265	15.8k
Glenn Dranoff United States	76	15.7k 2.3×	6.7k 1.1×	12.4k 2.3×	1.7k 0.8×	1.7k 1.0×	188	25.4k
Jonathan D. Powell United States	63	9.5k 1.4×	5.6k 0.9×	3.8k 0.7×	2.2k 1.0×	1.0k 0.6×	173	17.1k
Vincenzo Bronte Italy	78	21.1k 3.1×	6.7k 1.1×	11.2k 2.0×	2.7k 1.2×	1.2k 0.7×	183	29.0k
Rikard Holmdahl Sweden	89	13.1k 1.9×	6.3k 1.0×	4.1k 0.7×	1.4k 0.6×	2.1k 1.2×	636	27.5k
Ricky W. Johnstone Australia	77	5.3k 0.8×	18.7k 3.0×	7.8k 1.4×	2.2k 1.0×	1.3k 0.7×	248	25.4k
Christopher R. Parish Australia	64	7.7k 1.1×	7.4k 1.2×	2.2k 0.4×	1.2k 0.5×	1.2k 0.7×	330	18.5k
Lionel Apétoh France	52	10.9k 1.6×	4.4k 0.7×	8.6k 1.6×	1.1k 0.5×	642 0.4×	107	17.5k
James E. Talmadge United States	52	4.9k 0.7×	4.1k 0.7×	4.2k 0.8×	1.6k 0.7×	672 0.4×	251	11.7k
Reinhard Andreesen Germany	65	7.6k 1.1×	5.6k 0.9×	4.2k 0.8×	2.0k 0.9×	1.0k 0.6×	287	15.9k

Countries citing papers authored by Jianhua Yu

Since Specialization

Citations

This map shows the geographic impact of Jianhua Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianhua Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianhua Yu more than expected).

Fields of papers citing papers by Jianhua Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianhua Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianhua Yu. The network helps show where Jianhua Yu may publish in the future.

Co-authorship network of co-authors of Jianhua Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Jianhua Yu. A scholar is included among the top collaborators of Jianhua Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianhua Yu. Jianhua Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Rui, Xiaojin Wu, Lei Tian, et al.. (2025). NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity. Nature Communications. 16(1). 989–989.

Chen, Di, Jie Zhang, Guofu Li, et al.. (2024). Construction of atom-scale Co/Fe/Ni M-N-C active sites within nitrogen-doped carbon spheres for high-performance bifunctional oxygen catalysts in rechargeable zinc-air batteries. Journal of Energy Storage. 101. 113772–113772. 6 indexed citations

Li, Zhenlong, et al.. (2024). Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors. STAR Protocols. 5(3). 103096–103096. 1 indexed citations

Li, Zhenlong, Rui Ma, Jiamin Guo, et al.. (2024). Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell. 187(3). 624–641.e23. 41 indexed citations

Yu, Jianhua & Michael A. Caligiuri. (2023). Viral- and tumor-reactive natural killer cells. Seminars in Immunology. 67. 101749–101749. 7 indexed citations

Zhang, Wenhui, et al.. (2023). Dynamics of CD4+ T-Cells and Neutralizing Antibody Responses to Three Consecutive Doses of Inactivated COVID-19 Vaccines in PLWH. Infection and Drug Resistance. Volume 16. 2695–2707. 5 indexed citations

Wang, Junjun, et al.. (2023). A multifunctionally reversible detector: Photoacoustic and dual-channel fluorescence sensing for SO2/H2O2. Analytica Chimica Acta. 1263. 341181–341181. 9 indexed citations

Li, Xinxin, Xianchun Yan, Yufeng Wang, et al.. (2023). The Notch signaling pathway: a potential target for cancer immunotherapy. Journal of Hematology & Oncology. 16(1). 45–45. 92 indexed citations

Ren, Yulin, et al.. (2023). Vincamine, from an antioxidant and a cerebral vasodilator to its anticancer potential. Bioorganic & Medicinal Chemistry. 92. 117439–117439. 16 indexed citations

10.

Liu, Tao, Yang Yu, Qingya Luo, et al.. (2021). The RNA binding protein QKI5 suppresses ovarian cancer via downregulating transcriptional coactivator TAZ. Molecular Therapy — Nucleic Acids. 26. 388–400. 3 indexed citations

11.

Nalin, Ansel P., Christoph Weigel, Xiaoli Zhang, et al.. (2021). Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor. The Journal of Immunology. 207(6). 1672–1682. 6 indexed citations

12.

Dong, Wenjuan, Xiaojin Wu, Shoubao Ma, et al.. (2019). The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. Cancer Discovery. 9(10). 1422–1437. 221 indexed citations

13.

Xiao, Run, Stephen M. Bergin, Wei Huang, et al.. (2016). Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype. Cancer Immunology Research. 4(6). 488–497. 49 indexed citations

14.

Teng, Kun‐Yu, Jianfeng Han, Xiaoli Zhang, et al.. (2016). Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Molecular Cancer Therapeutics. 16(2). 312–322. 103 indexed citations

15.

Han, Jianfeng, Xilin Chen, Jianhong Chu, et al.. (2015). TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Research. 75(24). 5273–5282. 74 indexed citations

16.

Yoo, Ji Young, Brian Hurwitz, Chelsea Bolyard, et al.. (2014). Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects. Clinical Cancer Research. 20(14). 3787–3798. 64 indexed citations

17.

Chu, Jianhong, Shun He, Youcai Deng, et al.. (2014). Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells. Clinical Cancer Research. 20(15). 3989–4000. 92 indexed citations

18.

Zhao, Ran, Chunhua Han, Weiqiang Zhao, et al.. (2013). DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells. Molecular Cancer Research. 12(3). 370–380. 26 indexed citations

19.

Benson, Don M., Courtney E. Bakan, Anjali Mishra, et al.. (2010). The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood. 116(13). 2286–2294. 660 indexed citations breakdown →

20.

Benson, Don M., Jianhua Yu, Brian Becknell, et al.. (2008). Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 113(12). 2706–2714. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact